Incyte Corp

23 Sept 2026, 20:07 UTC

Incyte Corp shares are declining, despite social media highlighting its strength in the biotechnology sector, reflecting a cumulative decline since Tuesday's close.

22 Sept 2026, 23:45 UTC

Incyte Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 Sept 2026, 20:06 UTC

Incyte Corp's shares are declining despite announcing an expanded partnership with Specialised Therapeutics to commercialize ruxolitinib cream in Australia.

18 Sept 2026, 22:51 UTC

Incyte Corp is trading modestly higher in after-market hours, reflecting broader market trends amid mixed equity performance and rising treasury yields.

17 Sept 2026, 23:26 UTC

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

16 Sept 2026, 23:06 UTC

Incyte Corp is trading lower in after-market hours, marking its lowest point since the market closed and remaining below its 20-day moving average.

15 Sept 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

14 Sept 2026, 20:08 UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

11 Sept 2026, 22:01 UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

10 Sept 2026, 19:36 UTC

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

9 Sept 2026, 19:07 UTC

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.

8 Sept 2026, 20:02 UTC

Incyte Corp shares are lower today, driven by a downturn in the Biotechnology sub-sector. Analysts maintain a consensus "Moderate Buy" rating on the stock.

4 Sept 2026, 23:55 UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

3 Sept 2026, 19:16 UTC

Incyte Corp shares are lower amid broader market declines influenced by rising jobless claims. The stock remains above its 20-day moving average.

2 Sept 2026, 23:16 UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

1 Sept 2026, 22:06 UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

31 Aug 2026, 20:04 UTC

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

28 Aug 2026, 23:21 UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

27 Aug 2026, 20:07 UTC

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

26 Aug 2026, 19:36 UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

25 Aug 2026, 23:21 UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

24 Aug 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

21 Aug 2026, 19:46 UTC

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

20 Aug 2026, 23:41 UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

19 Aug 2026, 23:01 UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

17 Aug 2026, 20:06 UTC

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

14 Aug 2026, 19:36 UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

13 Aug 2026, 23:26 UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

10 Aug 2026, 19:36 UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

6 Aug 2026, 19:44 UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.